Latest News

Cantex Pharmaceuticals announced that Stephen Marcus, M.D., Chief Executive Officer, is participating in the BIO CEO & Investor Conference and is conducting one-on-one meetings with registered investors, showcasing the Company's business and clinical development strategy, recent corporate achievements, and anticipated milestones....

Cantex Pharmaceuticals and Michigan Medicine announced today the initiation of a randomized, double-blind, placebo-controlled, multicenter, Phase 3 pivotal clinical trial to evaluate the safety and efficacy of Cantex’s azeliragon in decreasing the incidence of acute kidney injury and other life-threatening complications in patients hospitalized for COVID-19....

Cantex Pharmaceuticals announced the publication in the peer-reviewed journal, npj Breast Cancer, reporting results from in vitro and in vivo models for triple-negative breast cancer showing suppression of metastasis and tumor progression by RAGE inhibition. Cantex’s azeliragon is a RAGE inhibitor that is orally administered and taken once daily....

Cantex Pharmaceuticals, Inc. today announced that it will present at the MedInvest Oncology Investor Conference being held June 21-22, 2023, in Boston, MA. Stephen G. Marcus, M.D. Cantex’s Chief Executive Officer, will present a corporate overview to strategics/big Pharma, VCs, family offices, hedge funds, and government/non-profit grantmakers....

Cantex’s azeliragon is an orally administered inhibitor of the receptor for advanced glycation end products (known as RAGE). Excessive activation of RAGE has been strongly implicated in life-threatening complications of COVID-19 infection, including lung and kidney failure. A protein produced by the immune system, known as “suPAR”, at high levels...